• Arrhythmias
• implantable cardioverter defibrillator (ICD)
• fractional flow reserve
• cardiac resynchronisation therapy
• coronary intervention (PCI)

The Authors' reply We thank Meune and Gobeaux for their interest1 in our recently published paper ‘Estimation of atrial fibrillation recency of onset and safety of cardioversion using NTproBNP levels in patients with unknown time of onset’.2

In response to their comments, we would like to point out that their first claim (“We first assume that these findings should not have direct clinical implications”) appears to be quite redundant, since it is clearly stated in our paper that “the present study is a proof-of-concept study (…). No clinical outcomes were evaluated and, thus, no specific recommendations regarding the clinical practice of atrial fibrillation (AF) patient management can be made on the basis of these findings.”

Regarding their second comment on the ‘selection bias’ of our cohort, we would like to point out the following. Their first argument …